Lead Product(s): Engineered Treg cell therapy product
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Quellis Biosciences Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2021
Under the terms of the agreement, IONTAS / FJB will provide Quell with a diverse panel of novel target binders, ranging in affinities, to enable Quell to select functional binders for chimeric antigen receptor (CAR) development against undisclosed targets.